Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Athersys Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

21 Aug 2015 Reuters Investment Profile 12 $20.00

Trading Report for (ATHX). A detailed report, including free correlated market analysis, and updates.

Detailed Trading Report for ATHX. Entry levels, target prices, and risk controls are integral. In addition, free market anal...

28 Aug 2015 Stock Traders Daily 6 $20.00

Thomson Reuters Stock Report - Athersys Inc (ATHX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

27 Aug 2015 Thomson Reuters Stock Report 11 $25.00

ATHERSYS INC (ATHX) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 Aug 2015 Pechala's Reports 1 $15.00

ValuEngine Rating and Forecast Report for ATHX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

22 Aug 2015 ValuEngine, Inc. 11 $25.00

ATHERSYS INC (ATHX) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

22 Aug 2015 Pechala's Reports 1 $25.00

Value Graph: ATHERSYS -- ATHX

21 Aug 2015 Ford Investor Services, Inc. 1 $12.00

ValuEngine Industry Report for Medical-Biomed/Genetics(ATHX)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

20 Aug 2015 ValuEngine, Inc. 10 $49.00

ATHERSYS - MORE CLARITY ON ISCHAEMIC STROKE

In its Q215 earnings release, Athersys provided much needed additional data with regard to its Phase II MultiStem trial in i...

19 Aug 2015 Edison Investment Research 6 $10.00

The Next Phase for MultiStem: Athersys' Gil Van Bokkelen

Regenerative medicine is surging toward the mainstream, and Athersys Inc. is riding the crest. Potential safety concerns surr...

12 Aug 2015 Streetwise Reports 6 $58.00